Adamas Pharmaceuticals Inc (ADMS) Stock Fundamental Analysis

USA • Nasdaq • NASDAQ:ADMS

8.22
+0.06 (+0.74%)
At close: Nov 23, 2021
8.3
+0.08 (+0.97%)
After Hours: 11/23/2021, 4:18:38 PM
Fundamental Rating

2

We assign a fundamental rating of 2 out of 10 to ADMS. ADMS was compared to 525 industry peers in the Biotechnology industry. ADMS may be in some trouble as it scores bad on both profitability and health. ADMS is valued quite expensively, but it does show have an excellent growth rating.


Dividend Valuation Growth Profitability Health

0

1. Profitability

1.1 Basic Checks

  • In the past year ADMS has reported negative net income.
ADMS Yearly Net Income VS EBIT VS OCF VS FCFADMS Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 -20M -40M -60M -80M -100M

1.2 Ratios

Industry RankSector Rank
ROA -43.55%
ROE N/A
ROIC N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ADMS Yearly ROA, ROE, ROICADMS Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 0 2K 4K 6K 8K 10K

1.3 Margins

Industry RankSector Rank
OM -44.55%
PM (TTM) -71.1%
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
ADMS Yearly Profit, Operating, Gross MarginsADMS Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 0 -5K -10K -15K

More info and screens

2

2. Health

2.1 Basic Checks

  • Compared to 1 year ago, ADMS has more shares outstanding
  • ADMS has a worse debt/assets ratio than last year.
ADMS Yearly Shares OutstandingADMS Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 5M 10M 15M 20M 25M
ADMS Yearly Total Debt VS Total AssetsADMS Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 50M 100M 150M 200M

2.2 Solvency

  • ADMS has an Altman-Z score of -3.57. This is a bad value and indicates that ADMS is not financially healthy and even has some risk of bankruptcy.
  • A Debt/Equity ratio of -5.76 indicates that ADMS is not too dependend on debt financing.
Industry RankSector Rank
Debt/Equity -5.76
Debt/FCF N/A
Altman-Z -3.57
ROIC/WACCN/A
WACCN/A
ADMS Yearly LT Debt VS Equity VS FCFADMS Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 0 50M -50M 100M -100M

2.3 Liquidity

  • A Current Ratio of 4.53 indicates that ADMS has no problem at all paying its short term obligations.
  • ADMS has a Quick Ratio of 4.17. This indicates that ADMS is financially healthy and has no problem in meeting its short term obligations.
Industry RankSector Rank
Current Ratio 4.53
Quick Ratio 4.17
ADMS Yearly Current Assets VS Current LiabilitesADMS Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 50M 100M 150M 200M

More info and screens

7

3. Growth

3.1 Past

  • ADMS shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 46.84%, which is quite impressive.
  • Looking at the last year, ADMS shows a very strong growth in Revenue. The Revenue has grown by 26.34%.
  • Measured over the past years, ADMS shows a very strong growth in Revenue. The Revenue has been growing by 107.84% on average per year.
EPS 1Y (TTM)46.84%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-1.87%
Revenue 1Y (TTM)26.34%
Revenue growth 3Y407.4%
Revenue growth 5Y107.84%
Sales Q2Q%28.33%

3.2 Future

  • The Earnings Per Share is expected to grow by 12.28% on average over the next years. This is quite good.
  • Based on estimates for the next years, ADMS will show a very strong growth in Revenue. The Revenue will grow by 20.86% on average per year.
EPS Next Y48.66%
EPS Next 2Y34.88%
EPS Next 3Y24.11%
EPS Next 5Y12.28%
Revenue Next Year26.58%
Revenue Next 2Y29.99%
Revenue Next 3Y21.96%
Revenue Next 5Y20.86%

3.3 Evolution

  • The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
ADMS Yearly Revenue VS EstimatesADMS Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 50M 100M 150M
ADMS Yearly EPS VS EstimatesADMS Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 -1 -2 -3 -4 -5

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for ADMS. In the last year negative earnings were reported.
  • Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for ADMS. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ADMS Price Earnings VS Forward Price EarningsADMS Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 -20 40

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA -10.88
ADMS Per share dataADMS EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1 -2

4.3 Compensation for Growth

  • A more expensive valuation may be justified as ADMS's earnings are expected to grow with 24.11% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y34.88%
EPS Next 3Y24.11%

More info and screens

0

5. Dividend

5.1 Amount

  • ADMS does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

Adamas Pharmaceuticals Inc / ADMS FAQ

What is the fundamental rating for ADMS stock?

ChartMill assigns a fundamental rating of 4 / 10 to ADMS.


What is the valuation status for ADMS stock?

ChartMill assigns a valuation rating of 0 / 10 to Adamas Pharmaceuticals Inc (ADMS). This can be considered as Overvalued.


What is the profitability of ADMS stock?

Adamas Pharmaceuticals Inc (ADMS) has a profitability rating of 3 / 10.


What is the financial health of Adamas Pharmaceuticals Inc (ADMS) stock?

The financial health rating of Adamas Pharmaceuticals Inc (ADMS) is 4 / 10.